Johnson & Johnson’s Tremfya Shows Crohn’s Disease Benefits Through Three Years
Johnson & Johnson has announced three-year clinical data showing that Tremfya (guselkumab) maintained clinical and endoscopic remission in adults with moderately to severely active…
Read More...
Read More...
